COMMENTARY: Merck to focus on underserved hep C groups after C-WORTHy
This article was originally published in Scrip
Executive Summary
Merck & Co created a stir with its the Phase II C-WORTHy study at European Association for the Study of the Liver in London on 10 April. Datamonitor Healthcare analyst Michael Haydock gives his take on the data.